Top

Published in:

01-09-2010

Impaired vascular function in asymptomatic young adult survivors of Hodgkin Lymphoma following mediastinal radiation

Authors: Shayna Zelcer, Breanna Chen, Joy Mangel, Olga Vujovic, Heather R. Thiessen-Philbrook, Michael Reider, Farid H. Mahmud

Published in: Journal of Cancer Survivorship | Issue 3/2010

Abstract

Background

Mediastinal radiation can accelerate atherosclerosis in Hodgkin lymphoma survivors (HLS), and early detection is optimal. Peripheral arterial tonometry (PAT), a non-invasive measure of endothelial function, is a surrogate marker of sub-clinical atherosclerosis. The objective of our study was to evaluate endothelial function in HLS and controls using PAT and to determine the influence of mediastinal radiation.

Procedure

Cross-sectional evaluation was performed on 26 HLS aged 12–30 years who were a minimum of 2 years from therapy, and their healthy age and gender matched controls. Evaluation included assessment for cardiovascular risk factors and completion of the Habitual Activity Estimation Score (HAES) questionnaire to assess activity level. Endothelial Function was measured using PAT hyperemia ratios (PAT-HR).

Results

HLS and controls were similar for baseline variables (mean age 23.3 ± 5 yrs vs. 23.4 ± 4.8 yrs, p = 0.92). HLS were on average 6.7 ± 4.6 yrs post treatment. No differences in endothelial function or cardiovascular risk factors were observed between HLS and controls. However, impaired endothelial function, as evidenced by lower PAT-HR (1.67 ± 0.39 vs. 2.03 ± 0.37, p < 0.01) was seen in HLS (n = 13) who received mediastinal radiation (mean radiation dose 2,600 ± 840 cGy) compared to controls.

Conclusions

Impaired endothelial function was preferentially observed in HLS who received mediastinal radiation, while no difference was observed between the HLS and control groups overall. This finding, assessed using a non invasive test of endothelial function, confirms that mediastinal radiation is an additional cardiovascular risk factor in this young cohort of patients. Further studies of endothelial function in this patient population are warranted.

Hudson M, Onciu M, Donaldson S. Hodgkin lymphoma. In: Pizzo P, Poplack D, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 695–721.

Adams MJ, Hardenbergh PH, Constine LS, et al. Radiation associated cardiovascular disease. Crit Rev Oncol Hematol. 2003;45:55–75.CrossRefPubMed

Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831–7.CrossRefPubMed

Heidenrich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal radiation. J Am Coll Cardiol. 2003;42(4):743–9.CrossRef

Brosius FC, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15–33 years) necropsy patients who received over 3500 rads to the heart. Am J Med. 1981;70(3):519–30.CrossRefPubMed

Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27(8):766–73.CrossRefPubMed

McEniery PT, Dorosti K, Shciavone W, et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol. 1987;60:1020–4.CrossRefPubMed

King V, Constine LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1996;36(4):881–9.PubMed

Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac risk after mediastinal irradiaton for Hodgkin’s disease. Radiother Oncol. 1998;46:51–62.CrossRefPubMed

10.

Constine LS, Schwartz RG, Savage DE, et al. Cardiac function, perfusion and morbidity in irradiated long-term survivors of Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1997;39(4):897–906.PubMed

11.

Reinders JG, Heijmen BJM, Olofsen-van Acht MJJ, et al. Ischemic heart disease after mantle field irradiation for Hodgkin’s disease in long-term follow-up. Radiother Oncol. 1999;51:35–42.CrossRefPubMed

12.

Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270(16):1949–55.CrossRefPubMed

13.

Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol. 1993;11(7):1208–15.PubMed

14.

Piovaccari G, Ferretti RM, Prati F, et al. Cardiac disease after chest irradiation for Hodgkin’s disease: incidence in 108 patients with long follow-up. Int J Cardiol. 1995;49:39–43.CrossRefPubMed

15.

Gustavsson A, Eskilsson J, Landberg T. Late cardiac effects after mantle radiotherapy in patients with Hodgkin’s disease. Ann Oncol. 1990;1:355–63.PubMed

16.

Silberberg JM, Zarrabi MH. Myocardial infarction in patients treated with mantle radiotherapy. J Clin Oncol. 1989;7:541–4.PubMed

17.

Lipshultz SE, Colan SD, Gleber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–15. 1992.CrossRefPubMed

18.

Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol. 2007;25:43–9.CrossRefPubMed

19.

Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:233–46.CrossRefPubMed

20.

Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235–41.CrossRefPubMed

21.

Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44(11):2137–41.CrossRefPubMed

22.

Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003;146(1):168–74.CrossRefPubMed

23.

Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol. 2003;41(10):1761–8.CrossRefPubMed

24.

Kuvin JT, Patel AR, Sliney NG, et al. Peripheral vascular endothelial function testing as a non-invasive indicator of coronary artery disease. J Am Coll Cardiol. 2001;38:1843–9.CrossRefPubMed

25.

Hamburg NH, Keyes MJ, Larson MG. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008;117:2467–74.CrossRefPubMed

26.

Mahmud FH, Van Uum S, Kanji N, et al. Impaired endothelial function in adolescents with type I diabetes melliutus. J Pediatr. 2008;152:557–62.CrossRefPubMed

27.

Mahmud FH, Hill DJ, Phil D, et al. Impaired vascular function in obese adolescents with insulin resistance. J Pediatr. 2009;155(5):678–82.CrossRefPubMed

28.

Tierney ES, Newburger JW, Gauvreau K, et al. Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. J Pediatr. 2009;154(6):901–5.CrossRef

29.

Hay JA, Atkinson S, Halton J. An examination of the reliability of the Habitual Activity Estimation Scale (HAES). In: Proceedings of the Pediatric Work Physiology Symposium, Odense, Denmark, 1995.

30.

Kuvin JT, Mammen A, Mooney P, et al. Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med. 2007;12:13–6.CrossRefPubMed

31.

Children’s Oncology Group (COG) Protocol AHODOO31. A phase III study of dose-intensive, response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate risk Hodgkin Disease (http://www.childrensoncologygroup.org).

32.

Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630–7.CrossRefPubMed

33.

Children’s Cancer Group (CCG) Protocol 5942. Comprehensive study of clinically staged Hodgkin’s Disease. Disease (http://www.childrensoncologygroup.org).

34.

Connors JM, Klimo P, Adams G, Burns BF, Cooper I, et al. Treatment of advanced Hodgkin’s disease with chemotherapy—comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1997;15:1638–45.PubMed

35.

Stewart JR, Fajardo LF, Gillette SM, et al. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31:1205–11.PubMed

36.

Theodoulou M, Seidman AD. Cardiac affects of adjuvant therapy for early breast cancer. Semin Oncol. 2003;30:730–9.CrossRefPubMed

37.

Beckman JA, Thakore A, Kalinowski BH, et al. Radiation therapy impairs endothelium-dependent vasodilation in humans. J Am Coll Cardiol. 2001;37:761–5.CrossRefPubMed

38.

Tribble DL, Barcellos-Hoff MH, Chu BM, et al. Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD-inhibitable processes. Arterioscler Thromb Vasc Biol. 1999;19:1387–92.PubMed

39.

Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review of on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):1–18.CrossRef

40.

Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 3.0. October 2008. http://www.survivorshipguidelines.org.

41.

Pihkala J, Happonen JM, Virtanen K, et al. Cardiopulmonary evaluation of exercise tolerance after chest irradiation and anticancer chemotherapy in children and adolescents. Pediatrics. 1995;95:722–6.PubMed

42.

Jurado J, Thompson PD. Prevention of coronary artery disease in cancer patients. Pediatr Blood Cancer. 2005;44:620–4.CrossRefPubMed

43.

Halcox JPJ, Deanfield JE. Endothelial cell function testing: how does the method help us in evaluating vascular status? Acta Paediatr Suppl. 2004;446:48–54.

44.

Celermajer DS, Sorenson KE, Bull C, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–5.CrossRefPubMed

45.

Haller MJ, Stein J, Shuster J, et al. Peripheral arterial tonometry demonstrates altered endothelial function in children with type I diabetes. Pediatr Diabetes 2007; 8(4):193–8.CrossRefPubMed

Title: Impaired vascular function in asymptomatic young adult survivors of Hodgkin Lymphoma following mediastinal radiation
Authors: Shayna Zelcer
Breanna Chen
Joy Mangel
Olga Vujovic
Heather R. Thiessen-Philbrook
Michael Reider
Farid H. Mahmud
Publication date: 01-09-2010
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 3/2010
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-010-0138-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Procedure

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2010

Adolescent behavior and adult health status in childhood cancer survivors

A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors

The Italian response to cancer survivorship research and practice: developing an evidence base for reform

Fertility in patients treated for testicular cancer

The out of pocket cost of breast cancer survivors: a review

Amelioration of sexual adverse effects in the early breast cancer patient

Keynote webinar | Spotlight on antibody–drug conjugates in cancer